Appendix S1

Appendices - Search strategy in the review

PubMed

("Ovarian Neoplasms"[Mesh] OR "ovarian cancer"[All Fields] OR "oophoroma"[All Fields] OR "carcinoma of ovary"[All Fields] OR "cervi*"[Title/Abstract] OR "uterine neck"[Title/Abstract] OR "neck of uterus"[Title/Abstract] OR "Cervix cancer"[All Fields] OR "Cervical cancer"[All Fields] OR "Cancer Cervix"[All Fields] OR "Cancer of the cervix" [All Fields] OR "cervix tumors"[All Fields] OR "endometrial cancer"[MeSH] OR "endometrium"[Title/Abstract] OR "uterus cancer"[Title/Abstract] OR "uterine cancer"[Title/Abstract] OR "corpus uteri cancer"[Title/Abstract] OR "endometrial cancer"[All Fields] OR "endometrial carcinoma"[All Fields] OR "endometrial neoplasia"[All Fields] OR "endometrial tumor"[All Fields] OR "endometrial neoplasm"[All Fields] OR "endometrial maligna"[All Fields] OR "uterine cancer"[All Fields] OR "uterine carcinoma"[All Fields] OR "uterine neoplasia"[All Fields] OR "uterine tumor"[All Fields] OR "uterine neoplasm"[All Fields] OR "uterine maligna"[All Fields]) AND ("survival rate"[Title/Abstract] OR "survival rates"[Title/Abstract] OR "survival analysis"[Title/Abstract] OR "survival analyses"[Title/Abstract] OR "survival*"[Title/Abstract] OR "survival rate"[Mesh] OR "survival analysis"[Mesh] OR "survival"[Mesh]) AND ("population-based"[Title/Abstract] OR "cancer registry"[Title/Abstract])

Web of Science

(TS="Ovarian Neoplasms" OR TS="ovarian cancer" OR TS="oophoroma" OR TS="carcinoma of ovary" OR TS="Cervix cancer" OR TS="Cervical cancer" OR TS="Cancer Cervix" OR TS="cervix tumors" OR TS="endometrial cancer" OR TS="uterus cancer" OR TS="corpus uteri cancer" OR TS="endometrial carcinoma" OR TS="endometrium" OR TS="endometrial neoplasia" OR TS="endometrial tumor" OR TS="endometrial neoplasm" OR TS="endometrial maligna" OR TS="uterine cancer" OR TS="uterine carcinoma" OR TS="uterine neoplasia" OR TS="uterine tumor" OR TS="uterine neoplasm" OR TS="uterine maligna")AND (TS="survival rate" OR TS="survival rates" OR TS="survival analysis" OR TS="survival analyses" OR TS=survival*) AND (TS="population-based" OR TS="cancer registry")

EMBASE

('neoplasm'/exp OR 'neoplasm' OR neoplas* OR tumor* OR tumour* OR cancer* OR hamartoma* OR incidentaloma* OR metasta* OR carcinoma* OR sarcoma* OR spheroid* OR adenocarcinoma* OR adenosarcoma*) AND ((('uterus'/exp OR 'uterus' OR 'uterine' OR endometri* OR 'uteri' OR 'ovary' OR 'ovary'/exp OR ovary OR ovarian OR 'cervix'/exp OR 'cervix' OR cervi* OR 'uterine'/exp OR uterine) AND ('neck'/exp OR neck) OR 'neck'/exp OR neck) AND of AND ('uterus'/exp OR uterus) OR 'cervix'/exp OR cervix OR cervical) AND (((((('survival rate'/exp OR 'survival rate' OR 'survival analysis'/exp OR 'survival analysis' OR 'survival' OR 'survival'/exp OR survival) AND rate OR 'survival'/exp OR survival) AND rates OR 'survival'/exp OR survival) AND ('analysis'/exp OR analysis) OR 'survival'/exp OR survival) AND analyses OR survival*) AND ('population based' OR 'cancer registry'/exp OR 'cancer registry')

SinoMed

(" Ovarian cancer "[all fields] OR "ovarian tumor "[all fields] OR" ovarian Neoplasms"[all fields] OR "ovarian cancer "[all fields] OR" ovarian tumor "[Mesh] OR "endometrial cancer "[all fields] OR "Endometrial Neoplasms"[all fields] OR "Endometrial Neoplasms"[all fields] OR "endometrial neoplasms "[all fields] OR" endometrial cancer "[all fields] OR "endometrial cancer

"[all fields] OR" endometrial cancer "[all fields] or "endometrial neoplasms "[Mesh] OR "Cervical Neoplasms"[all fields] OR" cervical neoplasms "[all fields] OR "cervical neoplasms "[all fields] OR" cervical neoplasms "[all fields] OR "cervical neoplasms "[all fields] OR" Cervical neoplasms "[Mesh]) AND (" Survival Rate"[all fields] OR" survival analysis "[all fields] OR" % survival rate "[all fields] OR" survival rate "[all fields] OR" survival rate "[Mesh]) AND (" population "[all fields] OR "population-based"[all fields] OR "Tumor registry"[all fields] OR "cancer Registry "[all fields] OR" Cancer Registry "[all fields] OR "cancer registry"[all fields] or "Registry "[Mesh])

Supplementary Table S1: PRISMA Checklist. PRISMA Checklist filled in for this review

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1 and 2 manuscript
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 3 manuscript
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 3 manuscript
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 3 manuscript
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 3 manuscript
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplement Appendices 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 3 manuscript, and Figure 1
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 3 manuscript
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each	Page 3 manuscript

Section and Topic	Item #	Checklist item	Location where item is reported
		study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	n.a.
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 4 manuscript
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	n.a.
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	n.a.
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 4 manuscript
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 4 manuscript
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	n.a.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	n.a.
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	n.a.
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	n.a
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	n.a
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in	Figure 1

Section and Topic	Item #	Checklist item	Location where item is reported
		the review, ideally using a flow diagram.	
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Supplement Table 12
Study characteristics	17	Cite each included study and present its characteristics.	Supplement Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	n.a
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2-4, Table 1-6
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	n.a
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Supplement Table 3-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	n.a
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	n.a.
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	n.a.
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	n.a
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 20 and 21 manuscript
	23b	Discuss any limitations of the evidence included in the review.	Page 22 manuscript
	23c	Discuss any limitations of the review processes used.	Page 22 manuscript
	23d	Discuss implications of the results for practice, policy, and future research.	Page 22 manuscript

Section and Topic	Item #	Checklist item	Location where item is reported
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	n.a
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	n.a
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	n.a
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	n.a
Competing interests	26	Declare any competing interests of review authors.	Page 22 manuscript
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	n.a

Supplementary Table S2: Characteristics of included studies

Author	Year	Title	Data source	ICD	DCO exclusion	Number of cases of cervical cancer	Number of cases of uterine cancer	Number of ovarian cancer cases
Wang Y, Wang J, Xu Y, et al	2022	Survival trend of cervical cancer in Qidong city of Jiangsu province from 1977 to 2016	Qidong City Center for Disease Control and Prevention	ICD-10	no	1546	unreported	unreported
Shimin D, Nan L, Yan L, et al	2014	Analysis of survival in major malignances during 2008－2013 in Jiulongpo avea of Chongqing	Jiulongpo District Center for Disease Control and Prevention	unreported	yes	252	125	166
Gong W, Luo S, Hu R, et al	2014	Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China	Zhejiang Provincial Center for Disease Control and Prevention	ICD-10	yes	4752	unreported	2046
Li Y, Lv Y, Lin W, et al	2017	Survival analysis of patients with malignant tumors in Sihui city between 1987 and 2009	Sihui City Cancer Registry	ICD-10/ICD-O-3	no	unreported	unreported	unreported

Zhou J, Su X, Li L, et al	2020	Survival rate among the main cancer patients in three countys of GuiZhou province,2013－2015	Guizhou Provincial Center for Disease Control and Prevention	ICD-10	no		354	unreported	unreported	
Zhang W, Wang L	2021	Analysis of cancer incidence and survival in Anshan City from 2008 to 2017	Anshan City Center for Disease Control and Prevention	ICD-10	no		2202	918		947
Han X, Huang C, Zhao J, et al	2014	Incidence and survival analysis of cervical cancer patients among permanent residents in Yangpu district of Shanghai during 2002－2012	Shanghai Yangpu District Center for Disease Control and Prevention	ICD-10/ICD-O-2	no		628	unreported	unreported	
Xiang Y, Jin F, Chen H, et al	1996	An analysis of survival rate of patients with malignancy in urban district of Shanghai from 1988 to 1991	Shanghai Cancer Registry	ICD-9	yes		612	590		183
Wang Q, lin X, Wang R, et al	2001	An analysis of relative survival rate in patients with malignancy in Tianjin	Tianjin Cancer Registry	ICD-9	unreported		955	252		385
Chiang CJ, Lo WC, Yang YW,et al	2016	Incidence and survival of adult cancer patients in Taiwan, 2002-2012	Taiwan Cancer Registry Database	ICD-O-3	unreported		8238	unreported	unreported	
Kim IS, Suh I, Oh HC, et al	1989	Incidence and survival of cancer in Kangwha County (1983-1987)	Kangwha County Cancer Registry	ICD-9	unreported	unreported		unreported	unreported	
Muhamad NA, Kamaluddin MA, Adon MY, et al	2015	Survival rates of cervical cancer patients in Malaysia	Malaysian National Cancer Registry and National Health Informatics Centre (NHIC)	unreported	unreported		5859	unreported	unreported	
Sriamporn S, Swaminathan R, Parkin DM, et al	2004	Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast Thailand	Khon Kaen province cancer registry	ICD-9	unreported		601	unreported	unreported	
Chia KS, Du WB, Sankaranarayanan R, et al	2001	Population-based cancer survival in Singapore, 1968 to 1992: an overview	Singapore Cancer Registry	unreported	yes	unreported		unreported	unreported	
Nandakumar A, Anantha N, Venugopal TC	1995	Incidence, mortality and survival in cancer of the cervix in Bangalore, India	Kidwai Memorial Institute of Oncology	ICD-9	yes		2423	unreported	unreported	
Yeole BB, Kumar AV,	2004	Population-based survival from cancers of breast, cervix and ovary in women in	Mumbai Population Cancer Registry	unreported	yes		1620	unreported		729

Kurkure A, Sunny L		Mumbai, India							
Swaminathan R, Selvakumaran R, Esmy PO, et al	2009	Cancer pattern and survival in a rural district in South India	Dindigul Ambilikkai Cancer Registry	ICD-10	yes	223	unreported		26
Fantin R, Santamaría-Ulloa C, Barboza-Solís C	2020	Social inequalities in cancer survival: a population-based study using the Costa Rican Cancer Registry	Costa Rican Cancer Registry	ICD-10	unreported	1257	962		514
Arias-Ortiz NE, de Vries E	2018	Health inequities and cancer survival in Manizales, Colombia: a population-based study	Manizales population-based Cancer Registry (MCR)	ICD-O-3	yes	226	unreported	unreported	
Booth CM, Li G, Zhang-Salomons J, Mackillop WJ	2010	The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada	Ontario Cancer Registry	ICD-9	unreported	1052	unreported	unreported	
Pearcey R, Miao Q, Kong W, et al	2007	Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study	Ontario Cancer Registry (OCR)	ICD-9	unreported	4069	unreported	unreported	
Graupera Boschmonar MC, Jiménez Chaviano PJ, Martín García AA, et al	1999	Trends in survival rates of cancer in Cuba	National Cancer Registry (NCR）	ICD-O	yes	1533	404	unreported	
Sant M, Allemani C, Santaquilani M,et al	2009	EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999.	82 cancer registries from 23 European countries	ICD-O-3	yes	37622	61820		60408
Melan K, Janky E, Macni J, et al	2017	Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002-2011)	Martinique Cancer Registry	ICD-O-3	unreported	306	unreported	unreported	
Levi F, Randimbison L, Te VC, et al	2000	Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993	Vaud Cancer Registry	ICD-9	yes	314	599		478
Gafà L, Amendola P, Dardanoni G, et al	1995	Cancers of the female genital tract in Ragusa, Sicily	Ragusa Cancer Registry	ICD-9	unreported	unreported	unreported	unreported	

Vincerževskiene I, Jasilionis D, Austys D, et al	2017	Education predicts cervical cancer survival: a Lithuanian cohort study	Lithuanian Cancer Registry	unreported	unreported		1866	unreported	unreported	
Bjurberg M, Holmberg E, Borgfeldt C, et al	2019	Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study	Swedish National Cancer Registry (NCR)	ICD-10	unreported		2141	unreported	unreported	
Brenner H, Hakulinen T	2008	Period versus cohort modeling of up-to-date cancer survival	Finnish Cancer Registry	unreported	unreported		725	3370		2656
Chakalova G, Dimitrova N, Gavrilov I, et al	2013	Cancer burden of breast and gynecological cancers in Bulgaria: epidemiology and clinical aspects	Bulgarian National Cancer Registry	ICD-10	unreported	unreported		unreported	unreported	
Waldmann A, Eisemann N, Katalinic A	2013	Epidemiology of malignant cervical, corpus uteri and ovarian tumours - current data and epidemiological trends	German Centre for Cancer Registry Data(ZfKD)	unreported	unreported	unreported		unreported	unreported	
Gondos A, Brenner H, Wabinga H, et al	2005	Cancer survival in Kampala, Uganda	The population-based Cancer Registry of Kampala, Uganda	unreported	yes		285	unreported		69
Wabinga H, Ramanakumar AV, Banura C, et al	2003	Survival of cervix cancer patients in Kampala, Uganda: 1995-1997	Kampala Cancer Registry	unreported	yes		261	unreported	unreported	
Dalton SO, Olsen MH, Johansen C, et al	2019	Socioeconomic inequality in cancer survival - changes over time. A population-based study, Denmark, 1987-2013	Danish Cancer Registry	ICD-10	unreported	unreported		3417		2825
Chen J, Zhu J, Zhang Y	2006	An analysis of survival in major malignancies during 1972-2000 in Qidong, China	Qidong City Center for Disease Control and Prevention	ICD-9/10	unreported		761	unreported		247
Li Y, Huang Q, Lin X, et al	2013	Survival rates of malignancies and nasopharyngeal carcinoma during 2003－2005 in Sihui city	Sihui City Cancer Registry	ICD-10	unreported		17	16		17
Arab M, Khayamzadeh M, Mohit M, et al	2009	Survival of ovarian cancer in Iran: 2000-2004	Cancer registry of Iran	unreported	yes	unreported		unreported		1246
Mahdy NH, Abdel-Fattah M, Ghanem H	1999	Ovarian cancer in Alexandria from 1988 to 1997: trends and survival	Alexandria Cancer Registry	unreported	unreported	unreported		unreported		358

De Angelis R, Sant M, Coleman MP, et al	2014	Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study	107 population-based cancer registries	ICD-O-3	yes	unreported	unreported	unreported	
Grann AF, Thomsen RW, Jacobsen JB, et al	2013	Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study	Danish National Registry	ICD-8/10	unreported	unreported	unreported		1540
Dahm-Kähler P, Borgfeldt C, Holmberg E, et al	2017	Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)	National Swedish Cancer Registry (NCR)	ICD-O-3	unreported	unreported	unreported		1678
Tretarre B, Molinie F, Woronoff AS, et al	2015	Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012	French cancer registries	ICD-O-3	unreported	unreported	unreported		4615
Brenner H, Stegmaier C, Ziegler H	1999	Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995	the population-based cancer registry of Saarland, Germany	ICD-9	unreported	unreported	unreported		2124
Zhou Y, Xiang ZS, Ma JY, et al	2021	Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study	Fujian Provincial Cancer Registry	ICD-O-3/ICD-10	yes	887	495		338
Li H, Du L, Li Q, et al	2020	Cancer survival in Haining and Jiashan cancer registry areas of Zhejiang province	Haining city and Jiashan county Cancer Registry	ICD-10	yes	538	360		324
Cheung FY, Mang OW, Law SC	2011	A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006	Hong Kong Cancer Registry (HKCaR)	ICD-O	yes	3807	unreported	unreported	
Yagi A, Ueda Y, Kakuda M, et al	2019	Epidemiologic and clinical analysis of cervical cancer using data from the population-based Osaka cancer registry	Osaka Cancer Registry	ICD-10	unreported	25826	unreported	unreported	
Matsuda T, Ajiki W, Marugame T, et al	2011	Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study	Miyagi,Yamagata, Niigata, Fukui, Osaka and Nagasaki Cancer Registry	ICD-10	yes	6716	3259		3916
Shin DW, Bae J, Ha J, et al	2012	Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study	Korean National Cancer Registry	ICD-O-3	unreported	78606	unreported	unreported	
Kang MJ, Won YJ, Lee JJ, et al	2022	Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019	Korea Central Cancer Registry	ICD-O-3	unreported	3273	3287		2888
Chung HH, Jang MJ,	2006	Cervical cancer incidence and survival in Korea: 1993-2002	Korea Central Cancer Registry and the	ICD-O	yes	44182	unreported	unreported	

Jung KW, et al			Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology.						
Maláková K, Cabasag CJ, Bardot A, et al	2022	Cancer survival in Thailand from 1997 to 2012: assessing the impact of universal health coverage	five Thai population-based cancer regis_x005f tries, namely Bangkok, Chiang Mai, Khon Kaen, Lampang, and Songkhla.	ICD-10	yes	3497(1997-2001), 5631(2002-2006),552 7(2008-2012)	unreported	unreported	
Laudico AV, Mirasol-Lumague MR, Mapua CA, et al	2010	Cancer incidence and survival in Metro Manila and Rizal province, Philippines	Philippine Cancer Society-Manila Cancer Registry and Department of Health-Rizal Cancer Registry	unreported	unreported	unreported	unreported	unreported	
Alawadhi E, Al-Awadi A, Elbasmi A, et al	2019	Cancer survival by stage at diagnosis in Kuwait: a population-based study	Kuwait Cancer Registry	ICD-O-3	yes	163	unreported		221
Gultekin M, Dundar S, Kucukyildiz I, et al	2017	Survival of gynecological cancers in Turkey: where are we at?	The National Central Cancer Registry of Turkey	ICD-O-3	unreported	351	713		489
Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, et al	2007	Trends in cervical cancer survival in Europe, 1983-1994: a population-based study	34 population-based cancer registries	ICD-9	yes	73022	unreported	unreported	
Gatta G, Lasota MB, Verdecchia A	1998	Survival of European women with gynaecological tumours, during the period 1978-1989	population-based cancer registries in 17 countries	ICD-O-3/ICD-9	yes	25350	27735		29107
Wenzel HHB, Bekkers RLM, Lemmens V,et al	2021	No improvement in survival of older women with cervical cancer-a nationwide study	Netherlands Cancer Registry	unreported	unreported	21644	unreported	unreported	
Brenner H, Hakulinen T	2001	Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry	Finnish Cancer Registry	unreported	yes	4033	11617		10789
Talbck M, Dickman PW	2012	Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004	Swedish National Cancer Registry (NCR)；. The Swedish Quality Registry for Gynecologic Cancer (SQRGC)	ICD-10	yes	2212	unreported	unreported	
Emmett M, Gildea C, Nordin A,et al	2018	Cervical cancer - does the morphological subtype affect survival rates?	National Cancer Data Repository (NCDR)	ICD-O-2/ICD-10	yes	12131	unreported	unreported	

Grundmann N, Meisinger C, Trepel M, et al	2020	Trends in cancer incidence and survival in the Augsburg study region-results from the Augsburg cancer registry	Augsburg cancer registry	ICD-10	yes		373	1022		703
Brenner H, Stegmaier C, Ziegler H	2005	Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium	the population-based Saarland Cancer Registry,	ICD-9	yes		1087	1874		1244
Levi F, La Vecchia C, Randimbison L, Te VC	1994	Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991	the population-based Vaud Cancer Registry	ICD-O/ICD-8	yes		695	unreported	unreported	
Houterman S, Janssen-Heijnen MLG, van de Poll-Franse LV, et al	2006	Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis	Eindhoven Cancer Registry	unreported	unreported	unreported		unreported	unreported	
Minelli L, Stracci F, Prandini S, et al	2004	Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998	population-based Cancer Registry of Umbria	ICD-9	yes		198	568		446
Ojamaa K, Innos K, Baburin A, et al	2018	Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014	Estonian Cancer Registry	ICD-O-3	yes		3403	unreported	unreported	
Ulinskas K, Aleknaviciene B, Smailyte G	2013	Demographic differences in cervical cancer survival in Lithuania	Lithuanian Cancer Registry	ICD-10	yes		6680	unreported	unreported	
Bravo LE, García LS, Collazos PA	2014	Cancer survival in Cali, Colombia: a population-based study, 1995-2004	Cancer Registry of Cali	ICD-10	yes		2469	unreported	unreported	
Hislop TG, Bajdik CD, Regier MD, et al	2007	Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada	British Columbia cancer registry	ICD-O	yes		3167	unreported	unreported	
Gari A, Lotocki R, Krepart G, et al	2008	Cervical cancer in the province of Manitoba: a 30-year experience	Manitoba Cancer Registry (MCR)	ICD-O/ICD-9	unreported		1927	unreported	unreported	
Jemal A, Ward EM, Johnson CJ, et al	2017	Annual report to the nation on the status of cancer, 1975-2014, featuring survival	the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI)	ICD-O/ICD-O-2/ICD-O-3/ICD-	yes	unreported		unreported	unreported	

				8/ICD-10					
Gatta G, Capocaccia R, Coleman MP, et al	2000	Toward a comparison of survival in American and European cancer patients	SEER database	ICD-9	yes	unreported	unreported	unreported	
Taylor R, Bell J, Coates M, et al	1996	Cervical cancer in New South Wales women: Five-year survival, 1972 to 1991	NSW Central Cancer Registry	unreported	unreported	6992	unreported	unreported	
Yu XQ, O'Connell DL, Gibberd RW, et al	2006	Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia	NSW Central Cancer Registry	ICD-O-2	yes	5957	5793		5375
Diaz A, Baade PD, Valery PC, et al	2018	Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012)	six Australian state-based cancer registries	ICD-10	unreported	4467	unreported	unreported	
Inoue S, Hosono S, Ito H, et al	2018	Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan	the population-based cancer registries of six prefectures (Yamagata, Miyagi, Fukui, Niigata, Osaka, and Nagasaki)	ICD-10/ICD-O-3	yes	unreported	8562	unreported	
Ioka A, Tsukuma H, Ajiki W, et al	2005	Influence of hospital procedure volume on uterine cancer survival in Osaka, Japan	Osaka Cancer Registry	ICD-10	yes	2035	499		61
Yagi A, Ueda Y, Ikeda S, et al	2022	Improved long-term survival of corpus cancer in Japan: a 40-year population-based analysis	Osaka Cancer Registry	ICD-10/ICD-O-3	unreported	unreported	15225	unreported	
Ha HI, Chang HK, Park SJ, et al	2021	The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry	Korea Central Cancer Registry	unreported	unreported	unreported	unreported	unreported	
Pavlík T, Májek O, Büchler T, et al	2014	Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008	Czech National Cancer Registry	unreported	yes	4870（2000-2004） 3777（2005-2009）	7392（2000-2004） 6288（2005-2009）	5190（2000-2004） 3668（2005-2009）	
Jensen KE, Hannibal CG, Nielsen A, et al	2008	Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003	nationwide registers	ICD-10	unreported	3007	3826		3855
Ojamaa K, Veerus P, Baburin A, et al	2019	Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades	Estonian Cancer Registry	ICD-10	yes	unreported	4281	unreported	
Dickman PW,	1999	Survival of cancer patients in Finland 1955-1994	Finnish Cancer Registry	ICD-7	yes	1464	5030		4126

Hakulinen T, Luostarinen T, et al									
Boll D, Verhoeven RH, van der Aa MA, et al	2012	Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008	the nationwide population-based Netherlands Cancer Registry (NCR)	ICD-O-3	unreported	unreported	30960	unreported	
Ioka A, Tsukuma H, Ajiki W,et al	2003	Ovarian cancer incidence and survival by histologic type in Osaka, Japan	Osaka Cancer Registry's data	ICD-10	yes	unreported	unreported		2431
Chung HH, Hwang SY, Jung KW, et al	2007	Ovarian cancer incidence and survival in Korea: 1993-2002	Korea Central Cancer Registry and the Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology	ICD-O	yes	unreported	unreported		11404
Shin D, Jung K, Bae J	2020	Conditional relative survival of ovarian cancer: a Korean national cancer registry study	Korean National Cancer Registry Study	ICD-O-3	unreported	unreported	unreported		25859
Ries LA	1993	Ovarian cancer. Survival and treatment differences by age.	SEER database	unreported	yes	unreported	unreported		20772
Cabasag CJ, Butler J, Arnold M, et al	2020	Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study	21 population-based cancer registries included Australia (New South Wales (NSW), Victoria, and Western Australia), Canada (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, Quebec, and Saskatchewan), Denmark,Ireland, New Zealand, Norway, and the United Kingdom (UK) (England,Northern Ireland, Scotland, and Wales)	ICD-10/ICD-O-3	yes	unreported	unreported		58161
Lambert P, Galloway K, Altman A, et al	2017	Ovarian cancer in Manitoba: trends in incidence and survival, 1992–2011	Manitoba Cancer Registry.	ICD-10	yes	unreported	unreported		1931
Karim-Kos HE, de Vries E, Soerjomataram I, et al	2008	Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s	21 European cancer registries, Denmark, Finland, Norway, Sweden, Ire_x005f land, and the United Kingdom，Austria,France, Germany, The	ICD-10	yes	unreported	unreported	unreported	

			Netherlands, and Switzerland，Croatia, Italy, Malta, Slovenia, and Spain，Czech Republic, Lithuania, and Poland						
Hamidou Z, Causeret S, Dabakuyo TS, et al	2010	Population-based study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years	Côte d'Or gynaecologic cancer registry	unreported	yes	unreported	unreported		748
Karim-Kos HE, Kiemeney LALM, Louwman MWJ, et al	2012	Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation	the population-based Netherlands Cancer Registry (NCR)	ICD-10	unreported	unreported	unreported	unreported	
Balvert-Locht HR, Coebergh JW, Hop WC, et al	1991	Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study	Eindhoven cancer registry：a population-based registry in the Southeast Netherlands	unreported	unreported	unreported	unreported		568
Jun J, Zhang Y, Chen Y, et al	2011	Analysis of survival rate of cervical cancer patients during 2001-2007 in Qidong City	Qidong City Center for Disease Control and Prevention	ICD-O-2	unreported	241	unreported	unreported	
Chen J, R S, Shen Z, et al	1998	Population-based cancer survival: an analysis of 16922 cases	Qidong City Center for Disease Control and Prevention	ICD-9	yes	200	unreported	unreported	
Lu H, Li L, Cheng Y, et al	2022	Timely estimates of 5-year relative survival for patients with cervical cancer: a period analysis using cancer registry data from Taizhou, Eastern China	four cancer registries with high-quality data from Taizhou, eastern China	ICD-10	yes	4314	unreported	unreported	
Ioka A, Ito Y, Tsukuma H	2007	Factors relating to poor survival rates of aged cervical cancer patients: a population-based study with the relative survival model in Osaka, Japan	Osaka Cancer Registry	ICD-10	unreported	10048	unreported	unreported	
Shin DW, Jung KW, Ha J, Bae J	2022	Conditional relative survival of patients with endometrial cancer: a Korean National Cancer Registry study	Korean National Cancer Registry	ICD-O-3	unreported	unreported	22131	unreported	
Vernooij F, Heintz APM, Witteveen PO,et al	2008	Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study	Netherlands Cancer Registry	ICD-10/ICD-O-2/3	yes	unreported	unreported		8621
De Rijke JM, Schouten LJ, Volovics A, et al	1998	Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986-92	the population-based Maastricht Cancer Registry（covers the regions of Middle and South Limburg）	unreported	yes	unreported	unreported		367

Stewart SL, Harewood R, Matz M, et al	2017	Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study	37 NPCR or SEER state-wide cancer registries	ICD-O-3	unreported	unreported	unreported		172849
Yoshida Y, Schmaltz CL, Jackson-Thompson J,et al	2018	Ovarian Cancer Survival in Missouri, 1996-2014	Missouri Cancer Registry	ICD-O-3	unreported	unreported	unreported		7046
Bjorge T, Thoresen SO, Skare GB	1993	Incidence, survival and mortality in cervical cancer in Norway, 1956-1990	Norwegian Cancer Registry	ICD-7	unreported	unreported	unreported		2687
Wong KH, Mang OWK, Au KH, et al	2012	Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study	the Hong Kong Cancer Registry (HKCaR)	ICD-9/10/ICD-O	yes	unreported	unreported		2941
van Altena AM, Karim-Kos HE, de Vries E, et al	2012	Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands	Netherlands Cancer Registry	ICD-O-3	yes	unreported	unreported		23399
Bennetsen AKK, Baandrup L, Aalborg GL, et al	2020	Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years	Danish Cancer Registry	ICD-O-3	yes	unreported	unreported		720
Wei K, Liang Z, Cen H	2016	Net survival of cancers in Zhongshan city,Guangdong province,1995－2009	Zhongshan City Cancer Registry	ICD-O-3	unreported	498	unreported		376
Wei K, Liang Z, Li Z	2020	Net survival of major cancers in Zhongshan city of Guangdong province from 2003 to 2013	Zhongshan City Cancer Registry	ICD-O-3	unreported	802	unreported		502
Allemani C, Matsuda T, Di Carlo V, et al	2018	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries	322 population-based cancer registries in 71 countries and territories	ICD-O-3	yes	527624	unreported		238719
Allemani C, Weir HK, Carreira H, et al	2015	Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)	279 population-based cancer registries in 67 countries	ICD-O-3	yes	602225	unreported		779302
Lim GH, Wong CS, Chow KY,et al	2009	Trends in long-term cancer survival in Singapore: 1968-2002	Singapore Cancer Registry	unreported	yes	unreported	unreported	unreported	

Zeng H, Chen W, Zheng R, et al	2018	Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries	17 cancer registries in China	ICD-10,ICD-O-3	unreported		11496	11531		8576
Quaresma M, Coleman MP, Rachet B	2015	40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: A population-based study	the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit	ICD-10	unreported		125676	171375		183451
Sant M, Lopez MDC, Agresti R, et al	2015	Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study	over 80 population-based cancer registries in 29 countries grouped into five European regions	ICD-O-3	unreported		104696	199046		157393
Antunes L, Roche L, José Bento M	2017	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study	the EUROCARE database for six European Latin countries: Belgium, France, Italy, Portugal, Spain and Switzerland	ICD-O-3	unreported	unreported		25508	unreported	
Antunes L, Santos LL, Bento MJ	2017	Survival from cancer in the north region of Portugal: results from the first decade of the millennium	he North Region Cancer Registry of Portugal database（RORENO database）	ICD-O-3,ICD-10	unreported		2254	2364		1184
Chen TH, Jansen L, Gondos A, et al	2012	Survival of endometrial cancer patients in Germany in the early 21st century: A period analysis by age, histology, and stage	a pooled German national dataset including data from 11 cancer registries	ICD-10,ICD-O-3	unreported	unreported		unreported	unreported	
Jansen L, Castro FA, Gondos A, et al	2015	Recent cancer survival in Germany: an analysis of common and less common cancers	11 population-based cancer registries covering 13 of 16 German federal states	ICD-10	yes		222005	43610		30196
Cowppli-Bony A, Uhry Z, Remontet L, et al	2017	Survival of solid cancer patients in France, 1989-2013: A population-based study	19 population-based cancer registries in the FRANCIM common database	ICD-O-3	unreported		2938	6582		4702
Innos K, Baburin A, Aareleid T	2014	Cancer patient survival in Estonia 1995-2009: Time trends and data quality	the Estonian Cancer Registry	ICD-10	yes		2335	2681		2207
Arnold M, Rutherford MJ, Bardot A, et al	2019	Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study	population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK)	ICD-10	unreported	unreported		unreported		215017
Caetano dos Santos FL, Wojciechowska U,	2022	Progress in cancer survival across last two decades: a nationwide study of over 1.2 million Polish patients diagnosed with the most common cancers	the Polish Cancer Registry (PLCR)	ICD-10	unreported		58056	unreported		64330

Michalek IM, et al									
Ojamaa K, Veerus P, Baburin A, et al	2017	Time trends in ovarian cancer survival in Estonia by age and stage	Estonian Cancer Registry(ECR)	ICD-O-3	yes	unreported	unreported		2296
Francis Okongo,David Martin Ogwang, Biying Liu, et al	2019	Cancer incidence in Northern Uganda (2013–2016)	Gulu Cancer Registry	ICD-O-3	unreported	486	7		19
Bo Nilsson, Evi Gustavson-Kadaka, Timo Hakulinen, et al	1997	Cancer survival in Estonian migrants to Sweden	National Swedish Cancer Registry (NCR)	unreported	yes	unreported	unreported		6008
Freddie Bray BSc,Jacques Ferlay ME,Isabelle Soerjomataram MD,et al	2018	Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	LOBOCAN 2018 database	ICD-10	unreported	unreported	unreported	unreported	
Gultekin M,Zayifoglu Karaca M,MDundar S.	2015	Gynecological cancer trends and 5-year survival in turkey: Analysis of 13.590 cancer patients	9 nationwide cancer registry centers	unreported	unreported	2745	6020		4240
Magdalena Bielska-Lasota, Silvia Rossi, Michalina Krzyżak et al	2020	Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study	EUROCARE-5 database	ICD-O-3	unreported	101714	unreported	unreported	
F Levi 1, L Randimbison, V C Te, S Franceschi, C La Vecchia	1992	Trend in cancer survival in Vaud, Switzerland	Vaud Cancer Registry	ICD-O	yes	194	313		210
A. Gondos,B. Holleczek,V. Arndt, et al	2007	Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?	Saarland Cancer Registry	ICD-9	yes	unreported	3530		2260

Note:-, No report or nonavailable in the original article.

Supplementary Table S3: Age-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1980-2018

Continent	County	Region	Period	＜44	45-54	55-64	65-74	75+
Asia	China	Qidong, Jiangsu[1+, 2]	1982-1991	-	43.8	41.7	28.0	6.9
			2001-2007	-	64.5	41.3	18.4	36.4
		Zhejiang[3]	2005-2010	83.8	76.7	67.5	56.3	42.1
		Taizhou, Zhejiang[4]	2014-2018	95.6	93.3	89.6	83.2	68.7
	India	Mumbai[5]+	1992-1994	-	49.4	26.3	20.8	48.0
	Japan	Osaka[6]+	1980-1984	-	-	68.7	52.8	
			1985-1989	-	-	72.6	52.3	
			1990-1994	-	-	69.4	56.4	
			1995-1999	-	-	63.6	53.3	
Europe[7-9]			1981-1983	73.0	63.0	62.0	48.0	29.0
			1984-1986	79.0	57.0	63.0	52.0	33.0
			1987-1989	76.0	64.0	58.0	55.0	43.0
			1989-1991	79.0	69.0	61.0	50.0	35.0
			1992-1994	79.0	68.0	59.0	48.0	31.0
			1995-1999	80.4	68.2	60.9	52.5	36.9
	Denmark[8]		1983-1994	83.0	68.0	58.0	55.0	29.0
	Finland[8]		1983-1994	80.0	66.0	61.0	48.0	37.0
	Iceland[8]		1983-1994	87.0	76.0	74.0	67.0	34.0
	Norway[8]		1983-1994	82.0	70.0	64.0	55.0	39.0
	Sweden[8]		1983-1994	85.0	74.0	60.0	52.0	41.0
	France[8]		1983-1994	81.0	70.0	67.0	60.0	38.0
	Germany[8]		1983-1994	76.0	57.0	65.0	60.0	38.0
	England[8]		1983-1994	78.0	65.0	58.0	47.0	31.0
	Scotland[8]		1983-1994	76.0	64.0	53.0	42.0	23.0
	Wales[8]		1983-1994	74.0	61.0	54.0	44.0	42.0
	Italy[8]		1983-1994	75.0	68.0	68.0	51.0	30.0
	Spain[8]		1983-1994	79.0	72.0	68.0	47.0	47.0
	Estonia[8]		1983-1994	60.0	57.0	58.0	56.0	29.0
	Poland[8]		1983-1994	65.0	55.0	44.0	37.0	20.0
	Slovakia[8]		1983-1994	71.0	66.0	55.0	44.0	28.0
	Slovenia[8]		1983-1994	76.0	61.0	53.0	48.0	27.0
	Netherlands[8, 10]*+		1983-1994	79.0	65.0	68.0	64.0	56.0
			1994-1998	85.0	68.0	66.0	50.0	36.0
			1999-2003	84.0	73.0	62.0	55.0	34.0
			2004-2008	86.0	74.0	62.0	51.0	40.0
			2009-2013	88.0	78.0	67.0	51.0	35.0
			2014-2018	88.0	77.0	70.0	54.0	34.0
			1989-2018	86.0	73.0	64.0	52.0	36.0

Switzerland[8]		1983-1994	78.0	70.0	64.0	51.0	39.0
	Vaud[11]	1980-1982	69.0		56.0	50.0	
		1983-1985	72.0		58.0	50.0	
		1986-1988	76.0		77.0	49.0	

Note:-, No report or nonavailable in the original article. * indicates statistically significant differences at different times in the original article. + indicates statistically significant differences between different groups (different ages) in the original article

Supplementary Table S4: Age-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1981-2016

Continent	County	Region	Period	＜44	45-54	55-64	65-74	75+
Europe[7,9]			1981-1983	92.0	82.0	78.0	69.0	54.0
			1984-1986	88.0	88.0	78.0	69.0	64.0
			1987-1989	87.0	85.0	80.0	71.0	56.0
			1995-1999	86.3	88.9	85.3	75.3	62.4
	Germany	Saarland[12]	1999-2003	80.7		88.6	72.9	72.7
	Estonia[13]		1996-2002	89.0		81.0	66.0	56.0
			2003-2009	89.0		78.0	72.0	52.0
			2010-2016	95.0		84.0	76.0	66.0
	France[14]		1992-1995	-	-	84.0	76.0	63.0
			1996-1999	-	-	85.0	77.0	65.0
			2000-2003	-	-	86.0	79.0	67.0
			2004-2007	-	-	86.0	80.0	69.0
	Italy[14]		1992-1996	-	-	86.0	79.0	68.0
			1996-2000	-	-	87.0	81.0	70.0
			2000-2004	-	-	88.0	82.0	72.0
			2004-2008	-	-	89.0	83.0	74.0
	Spain[14]		1992-1997	-	-	81.0	73.0	61.0
			1996-2001	-	-	83.0	76.0	64.0
			2000-2005	-	-	85.0	78.0	67.0
			2004-2009	-	-	86.0	80.0	70.0
	Switzerland[14]		1992-1998	-	-	88.0	81.0	69.0
			1996-2002	-	-	88.0	81.0	71.0
			2000-2006	-	-	87.0	81.0	73.0
			2004-2010	-	-	87.0	82.0	75.0
	Belgium[14]		2000-2007	-	-	89.0	82.0	71.0
			2004-2011	-	-	88.0	83.0	75.0
	Portugal[14]		2000-2008	-	-	80.0	72.0	62.0
			2004-2012	-	-	83.0	77.0	67.0

Note:-, No report or nonavailable in the original article.

Supplementary Table S5: Age-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2010

County	Region	Period	＜44	45-54	55-64	65-74	75+
China	Zhejiang[3]	2005-2010	74.3	54.2	45.9	44.2	41.8
India	Mumbai[5]+	1990-1994	-	28.1	13.8	5.7	12.7
Germany	Saarland[11,15]	1981-1985	41.7		36.7	21.1	
		1986-1990	54.8		30.8	24.0	
		1991-1995	60.1		42.9	26.5	
		1999-2003	72.1		49.1	37.2	21.7
United States[16]		1981-1987	67.3	45.9	36.3	26.5	18.7
Europe[8,17]		1981-1983	61.0	38.0	32.0	21.0	22.0
		1984-1986	70.0	46.0	34.0	22.0	18.0
		1987-1989	64.0	44.0	34.0	20.0	18.0
		1995-1999	71.3	54.7	42.2	32.0	20.7
		2000-2007	70.9	56.1	44.5	33.9	20.1
Europe(Northern)[18]		2000-2007	73.7	57.8	48.0	39.1	22.9
Europe(Central)[18]		2000-2007	71.8	58.6	47.5	37.7	22.7
Europe(Southern)[18]		2000-2007	73.4	58.1	47.1	33.7	18.1
Europe(Eastern)[18]		2000-2007	66.4	51.4	41.6	29.0	19.4
	UK and Ireland[18]	2000-2007	68.9	47.8	36.8	26.8	14.5
	France[19]	1989-2010	74.0	57.0	46.0	35.0	23.0

Note:-, No report or nonavailable in the original article. + indicates statistically significant differences between different groups (different ages) in the original article.

Supplementary Table S6-1: Stage-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1983-2019[#]

Continent	Country	Region	Period	Localized	Regional	Distant	Unknown
Asia	Korea[20,21]		1996-2015	91.9	72.3	27.0	73.9
			2015-2019	94.6	73.1	27.8	-
	Japan	Osaka[22]*	1987-1994	83.4	45.5	5.1	-
			1995-2002	84.5	47.8	3.5	-
			2003-2010	90.4	59.6	6.9	-
	Japan [d23]*		1993-1996	93.6	52.8	9.8	-
			1997-1999	92.3	53.1	12.8	-
	Thailand [e24]		1997-2001	94.6	81.6	45.3	85.5
			2002-2006	95	79.2	50.2	83.1
			2008-2012	96.4	81.8	30.9	76
	Kuwait[25]		2000-2004	54.4	59.3	-	80.4
			2005-2009	88.4	68.3	-	72.9
			2010-2013	-	94.7	-	62.2
	India	Mumbai[5]+	1992-1994	66.3	41.4	3.6	33.5
	Turkey[26]+		2009	80.0	50.0	22.0	57.0
Europe[27]			2000-2007	81.2	45.8	15.7	61.2
	Denmark[8]		1983-1994	83	51	25	-
	Finland[8]		1983-1994	84	52	27	-
	Norway[8]		1983-1994	85	58	22	-
	Germany	Saarland[8]	1983-1994	84	45	16	-
	Switzerland	Basel[8]	1983-1994	72	30	0	-
		Geneva[8]	1983-1994	83	59	23	-
	UK	East Anglia[8]	1983-1994	88	55	23	-
		Thames[8]	1983-1994	71	48	16	-
		West Midlands[8]	1983-1994	83	33	13	-
		Yorkshire[8]	1983-1994	79	52	26	-
	Italy	Tuscany[8]	1983-1994	78	59	19	-
		Varese[8]	1983-1994	78	48	3	-
	Estonia[8]		1983-1994	85	50	11	-
	Poland	Krakow[8]	1983-1994	57	38	15	-
	Slovakia[8]		1983-1994	78	19	12	-
	Slovenia[8]		1983-1994	82	43	12	-
			1987-1991	82.0	49.0	21.0	66.0
America	United States[28]		2013-2019	91.2	59.8	18.9	61.8

Note:* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

[d] Six registries (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) with high quality were included in the original article.

[e] Five Thai provinces (Bangkok, Chiang Mai, Khon Kaen, Lampang, and Songkhla) were included in the original article.

-, No report or nonavailable in the original article.

#Stage categories: localized, regional, distant and unknown.

Supplementary Table S6-2: Stage-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1983-2019 [#]

Continent	Country	Region	Period	I	II	III	IV	Unknown
Asia	China	Hong Kong[29]+	1997-2006	90.9	71.0	41.7	7.8	63.6
		Taiwan[30]	2004-2008	93.1	73.5	58.7	22.0	-
	Korea[31]+		1993-2002	94.2	69.7	38.9	21.1	-
Europe	Estonia[32]		2005-2009	96.0	72.0	52.0	24.0	49.0
			2010-2014	98.0	74.0	57.0	22.0	43.0
	Czech[33]		2000-2004	89.1	60.8*	43.7	10.0	-
			2005-2008	89.5	66.0*	46.9	11.4	-
	Lithuanian[34]		1990-1994	86.6	58.3	23.1	1.6	40.9
			1995-1999	87.0	64.0	34.4	5.6	53.0
			2000-2004	89.9	61.9	35.1	4.4	53.4

Note:[#]Stage categories: clinical stages of I, II, III, IV, and unknown.

-, No report or nonavailable in the original article.

* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

Supplementary Table S7-1: Stage-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1993-2019 #

Country	Period	Localized	Regional	Distant	Unknown
Korea[20, 35]	1997-2016	96.6	80.9	34.5	85.5
	2015-2019	96.6	82.2	31.7	-
Turkey[26]+	2009	92.0	66.0	38.0	87.0
Japan [d23, 36]	1993-1996	92.9	63.4*	22.7	-
	1997-1999	92.4	53.7*	17.2	-
	2001-2006	95.0*	63.8*	22.6*	-
Osaka,Japan[37]	2001-2012	94.2	64.4	19.1	-
United States[28]	2013-2019	94.9	69.8	18.4	57.6
Finland[38]	1985-1994	92.0	51.0	37.0	-

Note:[d] Six registries (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) with high quality were included in the original article.

-, No report or nonavailable in the original article.

* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article

[#]Stage categories: localized, regional, distant and unknown

Supplementary Table S7-2: Stage-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1993-2019 [#]

Country	Period	I	II	III	IV	Unknown
Czech[33]	2000-2004	88.8	72.1	47.0	18.8*	-
	2005-2008	91.5	73.5	50.1	19.4*	-

Note:-, No report or nonavailable in the original article.

[#]Stage categories: clinical stages of I, II, III, IV, and unknown.

* indicates statistically significant differences at different times in the original article.

Supplementary Table S8-1: Stage-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2019[#]

Country	Region	Period	Localized	Regional	Distant	Unknown
Korea[44]+		1997-2016	90.7	74.7	41.7	56.6
Japan[b23]		1993-1996	89.6	40.5	15.4	-
		1997-1999	86.0	43.5	20.3	-
India	Mumbai[5]+	1992-1994	54.7	20.4	4.6	21.8
Turkey[26]		2009	77.0	57.0	29.0	50.0
Kuwait[25]		2000-2004	100.0	36.0	6.4	-
		2005-2009	81.1	54.2	23.1	43.4
		2010-2013	-	61.6	0.1	60.6
Finland[38]		1985-1994	84.0	48.0	18.0	-
United States[28, 45]		2001-2003	84.8	53.9	25.2	33.1
		2004-2009	86.4	60.9	27.4	32.6
		2013-2019	92.4	72.9	31.5	36.4
	Missouri[46]	1996-2014	92.7	35.9		19.4

Note:-, No report or nonavailable in the original article.

[#]Stage categories: localized, regional, distant and unknown.

+ indicates statistically significant differences between different groups (different stages) in the original article.

Supplementary Table S8-2: Stage-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2019[#]

Country	Region	Period	I	II	III	IV	Unknown
Netherlands[39]		1996-2003	81.2	60.0	24.5	11.7	-
	Maastricht[40]	1986-1992	73.0		20.0		-
French[41]+		1982-2005	85.0	48.0	29.0	14.0	-
Czech[33]+		2000-2004	87.2	50.3*	29.1	14.2	-
		2005-2008	87.6	52.0*	32.7	13.4	-
Estonia[42]		1995-1999	82.0	48.0	25.0	11.0	41.0
		2000-2004	87.0	72.0	26.0	8.0	47.0
		2005-2009	91.0	67.0	35.0	16.0	18.0
Sweden[43]		2009-2013	79.0	72.0	33.0	20.0	-
United States[16]		1981-1987	83.9		20.7		21.6

Note: -, No report or nonavailable in the original article.

[#]Stage categories: clinical stages of I, II, III, IV, and unknown.

***** indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

Supplementary Table S9: Pathology-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1980-2018

Continent	Country	Region	Period	SCC(Squamous Cell Carcinoma)	ADC(Adenocarcinoma)	ASC(Adenosquamous Carcinoma)	Other	Unknown
Asia	China	Hong Kong[29]+	1997-2006	72.6	70.5	-	60.0	-
	Korea[21, 31]+		1993-2002	78.9	74.4	77.3	-	-
			1996-2015	82.6	78.5	79.2	60.0	63.7
	Turkey[26]		2009	64.0	56.0	-	-	-
Europe	Sweden[47]		2011-2015	75.7	79.6	72.0	33.8	-
	England[48]		2006-2008	64.6	65.3	55.0	51.8	-
	Estonia[32]+*		1995-1999	61.0	55.0	-	-	42.0
			2000-2004	65.0	66.0	-	-	33.0
			2005-2009	72.0	65.0	-	-	38.0
			2010-2014	71.0	63.0	-	-	30.0
	Netherlands[9]+*		1989-1993	67.0	65.0	60.0	48.0	89.0
			1994-1998	70.0	67.0	67.0	39.0	69.0
			1999-2003	71.0	70.0	61.0	40.0	64.0
			2004-2008	72.0	74.0	76.0	32.0	68.0
			2009-2013	75.0	72.0	73.0	45.0	39.0
			2014-2018	76.0	74.0	82.0	38.0	23.0
			1989-2018	72.0	71.0	70.0	40.0	70.0
	Canada	Manitoba[49]	1985-1999	68.0	65.0	-	-	-
	Switzerland	Vaud[10]	1980-1985	62.0	45.0	-	41.0	-
			1986-1991	68.0	75.0	-	40.0	-
	Norway[50]		1981-1985	69.8	68.1	-	-	-

Note:-, No report or nonavailable in the original article. * indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article

Supplementary Table S10: Pathology-specific 5-year relative/net survival rates (%) of endometrial cancer in selected countries and regions during 1989-2016

Country	Period	Endometrial adenocarcinoma	Mucinous adenocarcinoma	Serous carcinoma	Sarcomas	Carcinosarcoma	Clear cell carcinoma	Others
Korea[35]	1997-2016	93.2	90.9	60.5	-	51.5	74.8	72.6
Japan[36]*	1993-2000	84.5	-	-	-	41.7	-	67.6
	2001-2006	89.7	-	-	-	40.9	-	58.4
Turkey[26]+	2009	91.0	-	-	-	-	-	73.0
Netherlands[51]	1989-1993	82.0	77.0	73	47.0	34	55	-
	1994-1998	84.0	89.0	71	53.0	32	56	-
	1999-2003	86.0	84.0	56	46.0	35	55	-
	2004-2008	86.0	100.0	51	52.0	37	58	-
	1989-2008	85.0	87.0	66	49.0	35	57	-

Note:-, No report or nonavailable in the original article.

***** indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article.

Supplementary Table S11: Pathology-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1982-2016

Country	Regions	Period	All epithelial	Serous	Mucinous	Endometrioid	Clear cell	Epithelial, Not Otherwise Specified	Others	Germ cell	Sex cord-stromal	Mesenchymal
China	Hong Kong[52]+	1997-2006	63.1	44.6	86.0	77.8	69.4	31.7	-	-	-	-
French[19, 41]+		1982-2005		41.0	49.0		-	-	31.0	63.0		
		1989-2010	42	-	-	-	-	-	39.4	82.0	47.0	-
Netherlands[53]*		1989-1993	34.7	37.3	58.1	52.8	-	19.3	43.0	-	-	-
		1994-1998	36.0	36.8	56.7	59.7	-	20.8	34.8	-	-	-
		1999-2003	40.0	37.6	62.4	67.7	-	24.6	39.4	-	-	-
		2004-2009	41.1	38.5	64.1	69.9	-	21.4	42.2	-	-	-
	Maastricht[40]	1986-1992	36.0	37.0	59.0	65.0	56.0	22.0	-	-	-	-
Korea[44, 54]+		1993-2002	58.3	-	-	-	-	-	-	89.0	90.0	-
		1997-2016	-	57.4	76.3	78.4	75.1	-	40.6	-	-	-
United States	Missouri[46]	1996-2014	-	40.6	68.4	78.5	68.5	26.1	23.9	-	-	-
Denmark[55]		1988–1997	-	-	-	-	-	-	-	79.0	80.0	45.0
		1998–2007	-	-	-	-	-	-	-	78.0	90.0	58.0
		2008–2016	-	-	-	-	-	-	-	94.0	79.0	31.0
Sweden[43]		2009-2013	-	40.0	-	-	-	-	-	-	-	-
Japan	Osaka[56]	1985-1994	-	39.6	66.3	-	-	24.1	15.8	69.8	46.3	-
Turkey[26]+		2009	-	-	41.0	-	-	-	58.0	-	-	-

Note:-, No report or nonavailable in the original article.

***** indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article.

References for supplemental tables:

1. Jun J, Zhang Y, Chen Y, Ding L, Jianguo C. Analysis of survival rate of cervical cancer patients during 2001-2007 in Qidong City. *Chin J Clin Oncol Rehab.* 2011;18(3).
2. Chen J, R S, Shen Z, et al. Population-based cancer survival: an analysis of 16922 cases. *Chinese Journal of Oncology.* 1998;20(3).
3. Gong W, Luo S, Hu R, et al. Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China. *Chinese Journal of Preventive Medicine.* 2014(5).
4. Lu H, Li L, Cheng Y, et al. Timely Estimates of 5-Year Relative Survival for Patients With Cervical Cancer: A Period Analysis Using Cancer Registry Data From Taizhou, Eastern China. *Frontiers in public health.* 2022;10: 926058. https://doi.org/10.3389/fpubh.2022.926058.
5. Yeole BB, Kumar AV, Kurkure A, Sunny L. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. *Asian Pac J Cancer Prev.* 2004;5(3): 308-315.
6. Ioka A, Ito Y, Tsukuma H. Factors relating to poor survival rates of aged cervical cancer patients: A population-based study with the relative survival model in Osaka, Japan. *Asian Pacific Journal of Cancer Prevention.* 2009;10(3): 457-462.
7. Gatta G, Lasota MB, Verdecchia A, Grp EW. Survival of European women with gynaecological tumours, during the period 1978-1989. *European Journal of Cancer.* 1998;34(14): 2218-2225. https://doi.org/10.1016/s0959-8049(98)00326-8.
8. Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, Capocaccia R. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study. *Gynecol Oncol.* 2007;105(3): 609-619. https://doi.org/10.1016/j.ygyno.2007.01.048.
9. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. *Eur J Cancer.* 2009;45(6): 931-991. https://doi.org/10.1016/j.ejca.2008.11.018.
10. Wenzel HHB, Bekkers RLM, Lemmens V, Van der Aa MA, Nijman HW. No improvement in survival of older women with cervical cancer-A nationwide study. *Eur J Cancer.* 2021;151: 159-167. https://doi.org/10.1016/j.ejca.2021.04.014.
11. Levi F, La Vecchia C, Randimbison L, Te VC. Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991. *Ann Oncol.* 1994;5(8): 747-752. https://doi.org/10.1093/oxfordjournals.annonc.a058980.
12. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? *Annals of Oncology.* 2007;18(7): 1253-1259. https://doi.org/10.1093/annonc/mdm126.
13. Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K. Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. *Cancer Epidemiology.* 2019;62. https://doi.org/10.1016/j.canep.2019.101566.
14. Antunes L, Roche L, José Bento M. Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. *Eur J Cancer Prev.* 2017;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study: S100-s106. https://doi.org/10.1097/cej.0000000000000294.

15. Brenner H, Stegmaier C, Ziegler H. Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995. *Journal of Cancer Research and Clinical Oncology.* 1999;125(2): 109-113. https://doi.org/10.1007/s004320050250.
16. Ries LA. Ovarian cancer. Survival and treatment differences by age. *Cancer.* 1993;71(2 Suppl): 524-529. https://doi.org/10.1002/cncr.2820710206.
17. Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. *Eur J Cancer.* 1998;34(14 Spec No): 2218-2225. https://doi.org/10.1016/s0959-8049(98)00326-8.
18. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. *Lancet Oncology.* 2014;15(1): 23-34. https://doi.org/10.1016/s1470-2045(13)70546-1.
19. Tretarre B, Molinie F, Woronoff AS, et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. *Gynecologic Oncology.* 2015;139(2): 324-329. https://doi.org/10.1016/j.ygyno.2015.09.013.
20. Kang MJ, Won YJ, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. *Cancer Research and Treatment.* 2022;54(2): 330-344. https://doi.org/10.4143/crt.2022.128.
21. Shin DW, Bae J, Ha J, Jung KW. Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study. *J Gynecol Oncol.* 2021;32(1): e5. https://doi.org/10.3802/jgo.2021.32.e5.
22. Yagi A, Ueda Y, Kakuda M, et al. Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry. *Cancer Res.* 2019;79(6): 1252-1259. https://doi.org/10.1158/0008-5472.Can-18-3109.
23. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. *Jpn J Clin Oncol.* 2011;41(1): 40-51. https://doi.org/10.1093/jjco/hyq167.
24. Maláková K, Cabasag CJ, Bardot A, et al. Cancer survival in Thailand from 1997 to 2012: assessing the impact of universal health coverage. *J Cancer Policy.* 2022;34: 100353. https://doi.org/10.1016/j.jcpo.2022.100353.
25. Alawadhi E, Al-Awadi A, Elbasmi A, Coleman MP, Allemani C. Cancer Survival by Stage at Diagnosis in Kuwait: A Population-Based Study. *J Oncol.* 2019;2019: 8463195. https://doi.org/10.1155/2019/8463195.
26. Gultekin M, Dundar S, Kucukyildiz I, et al. Survival of gynecological cancers in Turkey: where are we at? *J Gynecol Oncol.* 2017;28(6): e85. https://doi.org/10.3802/jgo.2017.28.e85.
27. Bielska-Lasota M, Rossi S, Krzyżak M, et al. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. *Arch Gynecol Obstet.* 2020;301(2): 591-602. https://doi.org/10.1007/s00404-019-05412-5.
28. Surveillance Research Program NCI. SEER*Explorer: An interactive website for SEER cancer statistics.; Accessed 7 Jun 2023.
29. Cheung FY, Mang OW, Law SC. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. *Hong Kong Med J.* 2011;17(2): 89-95.

30. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. *J Formos Med Assoc.* 2016;115(12): 1076-1088. https://doi.org/10.1016/j.jfma.2015.10.011.
31. Chung HH, Jang MJ, Jung KW, et al. Cervical cancer incidence and survival in Korea: 1993-2002. *International Journal of Gynecological Cancer.* 2006;16(5): 1833-1838. https://doi.org/10.1111/j.1525-1438.2006.00708.x.
32. Ojamaa K, Innos K, Baburin A, Everaus H, Veerus P. Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014. *BMC Cancer.* 2018;18(1): 1075. https://doi.org/10.1186/s12885-018-5006-1.
33. Pavlík T, Májek O, Büchler T, et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. *Cancer Epidemiology.* 2014;38(1): 28-34. https://doi.org/10.1016/j.canep.2013.11.002.
34. Ulinskas K, Aleknaviciene B, Smailyte G. Demographic differences in cervical cancer survival in Lithuania. *Central European Journal of Medicine.* 2013;8(1): 16-21. https://doi.org/10.2478/s11536-012-0051-7.
35. Shin DW, Jung KW, Ha J, Bae J. Conditional relative survival of patients with endometrial cancer: a Korean National Cancer Registry study. *Journal of Gynecologic Oncology.* 2022;33(2). https://doi.org/10.3802/jgo.2022.33.e23.
36. Inoue S, Hosono S, Ito H, et al. Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan. *Journal of Epidemiology.* 2018;28(2): 75-80. https://doi.org/10.2188/jea.JE20170008.
37. Yagi A, Ueda Y, Ikeda S, et al. Improved long-term survival of corpus cancer in Japan: a 40-year population-based analysis. *International Journal of Cancer.* 2022;150(2): 232-242. https://doi.org/10.1002/ijc.33799.
38. Dickman PW, Hakulinen T, Luostarinen T, et al. Survival of cancer patients in Finland 1955-1994. *Acta Oncol.* 1999;38 Suppl 12: 1-103. https://doi.org/10.1080/028418699432996.
39. Vernooij F, Heintz APM, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. *Jnci-Journal of the National Cancer Institute.* 2008;100(6): 399-406. https://doi.org/10.1093/jnci/djn033.
40. De Rijke JM, Schouten LJ, Volovics A, Van der Putten H. Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986-92. *International Journal of Gynecological Cancer.* 1998;8(2): 150-157.
41. Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years. *Bmc Cancer.* 2010;10. https://doi.org/10.1186/1471-2407-10-622.
42. Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K. Time trends in ovarian cancer survival in Estonia by age and stage. *International Journal of Gynecological Cancer.* 2017;27(1): 44-49. https://doi.org/10.1097/igc.0000000000000858.
43. Dahm-Kähler P, Borgfeldt C, Holmberg E, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). *Gynecol Oncol.* 2017;144(1): 167-173. https://doi.org/10.1016/j.ygyno.2016.10.039.

44. Shin D, Jung K, Bae J. Conditional relative survival of ovarian cancer: a Korean national cancer registry study. *International Journal of Gynecological Cancer.* 2020;30(SUPPL 3): A87. https://doi.org/10.1136/ijgc-2020-IGCS.177.
45. Stewart SL, Harewood R, Matz M, et al. Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study. *Cancer.* 2017;123: 5138-5159. https://doi.org/10.1002/cncr.31027.
46. Yoshida Y, Schmaltz CL, Jackson-Thompson J, Simoes EJ. Ovarian cancer survival in Missouri, 1996-2014. *Mo Med.* 2018;115(6): 542-547.
47. Bjurberg M, Holmberg E, Borgfeldt C, et al. Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. *Gynecol Oncol.* 2019;155(2): 229-236. https://doi.org/10.1016/j.ygyno.2019.08.022.
48. Emmett M, Gildea C, Nordin A, Hirschowitz L, Poole J. Cervical cancer - does the morphological subtype affect survival rates? *J Obstet Gynaecol.* 2018;38(4): 548-555. https://doi.org/10.1080/01443615.2017.1379062.
49. Gari A, Lotocki R, Krepart G, Popowich S, Demers A. Cervical Cancer in the Province of Manitoba: A 30-Year Experience. *Journal of Obstetrics and Gynaecology Canada.* 2008;30(9): 788-795. https://doi.org/10.1016/S1701-2163(16)32943-7.
50. Bjorge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956-1990. *European Journal of Cancer Part A: General Topics.* 1993;29(16): 2291-2297. https://doi.org/10.1016/0959-8049(93)90224-4.
51. Boll D, Verhoeven RH, van der Aa MA, et al. Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008. *Int J Gynecol Cancer.* 2012;22(4): 599-606. https://doi.org/10.1097/IGC.0b013e318244cedc.
52. Wong KH, Mang OWK, Au KH, Law SCK. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. *Hong Kong Medical Journal.* 2012;18(6): 466-474.
53. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. *Gynecol Oncol.* 2012;125(3): 649-654. https://doi.org/10.1016/j.ygyno.2012.02.033.
54. Chung HH, Hwang SY, Jung KW, et al. Ovarian cancer incidence and survival in Korea: 1993-2002. *Int J Gynecol Cancer.* 2007;17(3): 595-600. https://doi.org/10.1111/j.1525-1438.2007.00824.x.
55. Bennetsen AKK, Baandrup L, Aalborg GL, Kjaer SK. Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years. *Gynecologic Oncology.* 2020;157(3): 693-699. https://doi.org/10.1016/j.ygyno.2020.03.021.
56. Ioka A, Tsukuma H, Ajiki W, Oshima A. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. *Cancer Science.* 2003;94(3): 292-296.